insulin aspart Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4981 116094-23-6

Description:

MoleculeDescription

Synonyms:

  • insulin aspart protamine recombinant
  • insulin aspart protamine
  • insulin aspart protamine crystalline
  • insulin aspart
  • insulin aspart recombinant
  • novolog
  • insulin aspart [rDNA origin]
  • novorapid
Insulin that has been modified to contain an ASPARTIC ACID instead of a PROLINE at position 38 of the B-chain.
  • Molecular weight: 5825.60
  • Formula: C256H381N65O79S6
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA: 2345.16
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
40 U P
40 U P
40 U P

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Sept. 20, 2019 PMDA Novo Nordisk Pharma Ltd.
Sept. 7, 1999 EMA
June 7, 2000 FDA NOVO NORDISK INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Diabetic ketoacidosis 1316.21 10.34 539 45432 17671 46622420
Hypoglycaemia 1233.43 10.34 729 45242 53620 46586471
Blood glucose increased 1102.08 10.34 753 45218 71260 46568831
Hyperglycaemia 368.77 10.34 293 45678 34778 46605313
Blood glucose decreased 354.95 10.34 225 45746 18667 46621424
Diabetes mellitus inadequate control 354.43 10.34 198 45773 13016 46627075
Ketoacidosis 231.81 10.34 101 45870 3854 46636237
Glycosylated haemoglobin increased 215.46 10.34 134 45837 10742 46629349
Hypoglycaemic unconsciousness 178.83 10.34 54 45917 692 46639399
Diabetic retinopathy 175.87 10.34 71 45900 2231 46637860
Hypoglycaemic coma 171.55 10.34 72 45899 2502 46637589
Exposure during pregnancy 149.01 10.34 329 45642 107883 46532208
Blood glucose fluctuation 144.54 10.34 74 45897 4072 46636019
Product leakage 143.74 10.34 39 45932 330 46639761
Acute kidney injury 121.90 10.34 507 45464 235348 46404743
Drug ineffective 111.32 10.34 323 45648 677515 45962576
Rheumatoid arthritis 94.57 10.34 60 45911 240155 46399936
Blood glucose abnormal 79.31 10.34 60 45911 6612 46633479
Completed suicide 75.12 10.34 25 45946 145895 46494196
Hypoglycaemia unawareness 73.04 10.34 18 45953 99 46639992
Hypoglycaemic seizure 72.82 10.34 25 45946 493 46639598
Diabetes mellitus 71.98 10.34 155 45816 49910 46590181
Diabetic metabolic decompensation 68.58 10.34 30 45941 1155 46638936
Diabetic neuropathy 68.32 10.34 44 45927 3745 46636346
Anti-insulin antibody positive 60.64 10.34 15 45956 84 46640007
Ketosis 59.28 10.34 21 45950 456 46639635
Hypoglycaemia neonatal 58.39 10.34 25 45946 913 46639178
Liquid product physical issue 58.18 10.34 22 45949 578 46639513
Premature baby 57.95 10.34 80 45891 18032 46622059
Drug intolerance 57.44 10.34 37 45934 147012 46493079
Diabetic ketosis 55.79 10.34 16 45955 169 46639922
Lactic acidosis 54.60 10.34 110 45861 33799 46606292
Product quality issue 54.28 10.34 113 45858 35535 46604556
Treatment failure 51.42 10.34 14 45957 93073 46547018
Toxicity to various agents 51.11 10.34 81 45890 211685 46428406
Drug hypersensitivity 50.98 10.34 102 45869 243723 46396368
Arthralgia 48.43 10.34 190 45781 364413 46275678
Pain 47.34 10.34 276 45695 476672 46163419
Arthropathy 44.47 10.34 14 45957 84686 46555405
Ketonuria 44.06 10.34 16 45955 374 46639717
Bicuspid aortic valve 43.18 10.34 12 45959 112 46639979
Pre-eclampsia 41.34 10.34 45 45926 7949 46632142
Wrong product administered 40.70 10.34 38 45933 5592 46634499
Synovitis 40.34 10.34 6 45965 61069 46579022
Joint swelling 39.60 10.34 64 45907 166009 46474082
Conjunctival abrasion 39.49 10.34 9 45962 33 46640058
Diabetic nephropathy 38.03 10.34 21 45950 1347 46638744
Euglycaemic diabetic ketoacidosis 37.81 10.34 24 45947 1992 46638099
Contraindicated product administered 37.27 10.34 16 45955 79931 46560160
Hyperkalaemia 36.98 10.34 122 45849 50587 46589504
Caesarean section 35.69 10.34 61 45910 16542 46623549
Insulin resistance 35.07 10.34 16 45955 681 46639410
Chronic kidney disease 35.03 10.34 104 45867 40767 46599324
Alopecia 34.73 10.34 67 45904 162347 46477744
Congenital aortic valve stenosis 34.30 10.34 9 45962 66 46640025
Renal failure 34.24 10.34 210 45761 113384 46526707
Type 1 diabetes mellitus 34.21 10.34 26 45945 2884 46637207
Infusion related reaction 32.51 10.34 31 45940 101177 46538914
Systemic lupus erythematosus 32.09 10.34 12 45959 65168 46574923
Neonatal respiratory distress syndrome 30.59 10.34 23 45948 2510 46637581
Infective pulmonary exacerbation of cystic fibrosis 30.54 10.34 45 45926 10762 46629329
Hyper IgE syndrome 28.41 10.34 10 45961 213 46639878
Musculoskeletal stiffness 28.13 10.34 33 45938 97960 46542131
Blood ketone body 28.03 10.34 7 45964 41 46640050
Polyuria 28.00 10.34 35 45936 7160 46632931
Therapeutic product effect incomplete 27.44 10.34 22 45949 78131 46561960
Therapeutic product effect decreased 26.88 10.34 25 45946 82576 46557515
Hypoglycaemic encephalopathy 26.15 10.34 10 45961 271 46639820
Lipodystrophy acquired 25.96 10.34 17 45954 1488 46638603
Pancreatitis 25.82 10.34 98 45873 43529 46596562
Bladder agenesis 25.27 10.34 8 45963 121 46639970
Foetal exposure during pregnancy 25.18 10.34 77 45894 30670 46609421
HELLP syndrome 25.15 10.34 14 45957 912 46639179
Cloacal exstrophy 24.80 10.34 8 45963 129 46639962
Diabetic gastroparesis 24.29 10.34 9 45962 223 46639868
Dehydration 24.28 10.34 252 45719 159288 46480803
Gastrointestinal malformation 23.93 10.34 8 45963 145 46639946
Device failure 23.21 10.34 29 45942 5930 46634161
Lethargy 22.51 10.34 105 45866 51066 46589025
Sinusitis 21.72 10.34 61 45910 129707 46510384
Anti-insulin antibody increased 21.59 10.34 6 45965 56 46640035
Congenital genital malformation 21.46 10.34 7 45964 117 46639974
Tethered cord syndrome 21.20 10.34 8 45963 209 46639882
International normalised ratio abnormal 20.88 10.34 20 45951 3039 46637052
Caudal regression syndrome 20.83 10.34 7 45964 129 46639962
Impaired gastric emptying 20.52 10.34 32 45939 8040 46632051
Genitalia external ambiguous 20.49 10.34 7 45964 136 46639955
Diabetic foot 19.97 10.34 15 45956 1635 46638456
Meconium stain 19.18 10.34 7 45964 166 46639925
Glossodynia 18.96 10.34 10 45961 44363 46595728
Atrial septal defect 18.81 10.34 27 45944 6305 46633786
Diabetic hyperosmolar coma 18.54 10.34 9 45962 441 46639650
Gastrointestinal disorder congenital 18.41 10.34 6 45965 100 46639991
Large intestine polyp 18.39 10.34 30 45941 7831 46632260
Fear-related avoidance of activities 18.25 10.34 6 45965 103 46639988
Acute painful neuropathy of rapid glycaemic control 17.77 10.34 3 45968 0 46640091
Hyperglycaemic unconsciousness 17.77 10.34 3 45968 0 46640091
Cystic fibrosis 17.76 10.34 20 45951 3668 46636423
Hospitalisation 17.73 10.34 115 45856 63270 46576821
Gastroschisis 17.70 10.34 7 45964 208 46639883
Product physical issue 17.65 10.34 23 45948 4904 46635187
Device expulsion 17.52 10.34 3 45968 27539 46612552
Loss of consciousness 16.95 10.34 172 45799 108066 46532025
Headache 16.95 10.34 351 45620 478001 46162090
Anal atresia 16.90 10.34 8 45963 371 46639720
Abdominal discomfort 16.84 10.34 84 45887 151081 46489010
Decreased insulin requirement 16.82 10.34 6 45965 133 46639958
Restrictive pulmonary disease 16.77 10.34 12 45959 1214 46638877
Acute myocardial infarction 16.70 10.34 69 45902 31855 46608236
Macrosomia 16.63 10.34 5 45966 63 46640028
Congenital ectopic bladder 16.49 10.34 5 45966 65 46640026
Nasopharyngitis 16.35 10.34 87 45884 153911 46486180
Diabetic ketoacidotic hyperglycaemic coma 16.22 10.34 5 45966 69 46640022
Blood ketone body increased 15.92 10.34 7 45964 273 46639818
Accidental underdose 15.86 10.34 9 45962 609 46639482
Cholestasis 15.57 10.34 60 45911 26833 46613258
Oesophageal spasm 15.50 10.34 14 45957 1975 46638116
Foetal hypokinesia 15.46 10.34 8 45963 450 46639641
Febrile neutropenia 15.45 10.34 45 45926 94582 46545509
Hepatic encephalopathy 15.22 10.34 32 45939 10125 46629966
Premature delivery 15.11 10.34 52 45919 22017 46618074
Pemphigoid 15.08 10.34 23 45948 5668 46634423
Resting tremor 15.06 10.34 9 45962 671 46639420
Hyperhidrosis 14.99 10.34 144 45827 89164 46550927
Product administration error 14.92 10.34 48 45923 19633 46620458
Meningomyelocele 14.86 10.34 8 45963 488 46639603
Anencephaly 14.81 10.34 6 45965 190 46639901
Congenital mitral valve incompetence 14.52 10.34 4 45967 36 46640055
Left ventricular hypertrophy 14.51 10.34 21 45950 4942 46635149
Foetal distress syndrome 14.30 10.34 11 45960 1242 46638849
Rhabdomyolysis 14.24 10.34 80 45891 41829 46598262
Retinal aneurysm 14.22 10.34 6 45965 211 46639880
Dialysis 14.16 10.34 31 45940 10085 46630006
Device operational issue 14.15 10.34 6 45965 214 46639877
Congenital anomaly 14.13 10.34 12 45959 1560 46638531
Fatigue 14.07 10.34 475 45496 608222 46031869
Maculopathy 13.87 10.34 12 45959 1599 46638492
Myocardial infarction 13.86 10.34 152 45819 97376 46542715
Mobility decreased 13.82 10.34 24 45947 60570 46579521
Multiple lentigines syndrome 13.67 10.34 6 45965 233 46639858
Carcinoid crisis 13.41 10.34 6 45965 244 46639847
Spine malformation 13.36 10.34 6 45965 246 46639845
Heart sounds 13.34 10.34 6 45965 247 46639844
Suicide attempt 13.10 10.34 96 45875 54940 46585151
Jaundice neonatal 13.09 10.34 9 45962 854 46639237
Type 2 diabetes mellitus 12.89 10.34 46 45925 19829 46620262
Immunosuppressant drug level increased 12.83 10.34 16 45955 3266 46636825
Congenital musculoskeletal anomaly 12.81 10.34 7 45964 440 46639651
Conjoined twins 12.74 10.34 6 45965 275 46639816
Oesophageal pain 12.60 10.34 14 45957 2529 46637562
Pericarditis 12.47 10.34 4 45967 23923 46616168
Foetal macrosomia 12.37 10.34 4 45967 65 46640026
High risk pregnancy 12.27 10.34 5 45966 161 46639930
Diabetic retinal oedema 12.19 10.34 7 45964 484 46639607
Pyelonephritis 12.14 10.34 38 45933 15319 46624772
White blood cell count decreased 12.13 10.34 63 45908 112168 46527923
Acidosis 12.12 10.34 31 45940 11143 46628948
Blood ketone body present 12.10 10.34 3 45968 17 46640074
Neutrophil count decreased 12.06 10.34 15 45956 43411 46596680
Intentional overdose 12.05 10.34 107 45864 64837 46575254
Abdominal pain 12.03 10.34 304 45667 229727 46410364
Cerebrovascular accident 11.94 10.34 152 45819 100887 46539204
Injection site abscess 11.91 10.34 9 45962 990 46639101
Hyperglycaemic hyperosmolar nonketotic syndrome 11.68 10.34 7 45964 524 46639567
Polyhydramnios 11.66 10.34 12 45959 1987 46638104
Vomiting 11.65 10.34 551 45420 452243 46187848
Death 11.62 10.34 247 45724 335301 46304790
Exomphalos 11.59 10.34 7 45964 532 46639559
Lipoatrophy 11.54 10.34 6 45965 341 46639750
Diabetic coma 11.53 10.34 8 45963 770 46639321
Pancreas transplant 11.43 10.34 3 45968 22 46640069
Polymorphic light eruption 11.43 10.34 3 45968 22 46640069
Pancreatic carcinoma 11.43 10.34 22 45949 6535 46633556
Fluid overload 11.38 10.34 55 45916 27130 46612961
Neural tube defect 11.37 10.34 5 45966 195 46639896
Polycystic ovaries 11.29 10.34 10 45961 1374 46638717
Bone pain 11.22 10.34 18 45953 46872 46593219
Incorrect dose administered 11.16 10.34 80 45891 45470 46594621
Blood pressure diastolic decreased 11.09 10.34 35 45936 14176 46625915
Prolonged expiration 10.99 10.34 6 45965 376 46639715
Glucose-6-phosphate dehydrogenase deficiency 10.96 10.34 5 45966 213 46639878
Bursitis 10.92 10.34 3 45968 19839 46620252
Anogenital warts 10.91 10.34 6 45965 382 46639709
Umbilical cord abnormality 10.88 10.34 7 45964 595 46639496
Therapeutic response decreased 10.87 10.34 16 45955 43129 46596962
Product container issue 10.86 10.34 11 45960 1788 46638303
Sleep apnoea syndrome 10.84 10.34 47 45924 22154 46617937
Adrenal adenoma 10.73 10.34 8 45963 862 46639229
Knee arthroplasty 10.61 10.34 5 45966 23660 46616431
Sepsis neonatal 10.61 10.34 6 45965 403 46639688
Median nerve injury 10.61 10.34 3 45968 30 46640061
Ataxia 10.59 10.34 34 45937 13896 46626195
Off label use 10.57 10.34 289 45682 379552 46260539
Cataract subcapsular 10.49 10.34 7 45964 632 46639459
Device malfunction 10.49 10.34 33 45938 13341 46626750
Drug abuse 10.46 10.34 30 45941 63378 46576713
Hepatocellular injury 10.46 10.34 57 45914 29465 46610626
Hypothermia 10.43 10.34 31 45940 12152 46627939

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypoglycaemia 1185.32 10.40 795 41928 50186 29859569
Blood glucose increased 605.88 10.40 580 42143 60950 29848805
Diabetic ketoacidosis 605.41 10.40 341 42382 15645 29894110
Blood glucose decreased 303.39 10.40 204 42519 12849 29896906
Diabetes mellitus inadequate control 302.75 10.40 202 42521 12560 29897195
Hypoglycaemic unconsciousness 226.21 10.40 72 42651 744 29909011
Hypoglycaemic coma 213.57 10.40 91 42632 2240 29907515
Hyperglycaemia 213.37 10.40 257 42466 34943 29874812
Blood glucose fluctuation 165.86 10.40 88 42635 3573 29906182
Ketoacidosis 100.30 10.40 64 42659 3682 29906073
Glycosylated haemoglobin increased 88.46 10.40 87 42636 9404 29900351
Drug abuse 82.60 10.40 10 42713 82062 29827693
Anti-insulin antibody positive 81.18 10.40 24 42699 189 29909566
Toxicity to various agents 79.91 10.40 81 42642 177102 29732653
Diabetic retinopathy 79.08 10.40 42 42681 1708 29908047
Completed suicide 73.66 10.40 25 42698 99467 29810288
Acute kidney injury 73.47 10.40 652 42071 273190 29636565
Hypoglycaemic seizure 72.46 10.40 24 42699 284 29909471
Hypoglycaemia neonatal 55.11 10.40 32 42691 1551 29908204
Blood glucose abnormal 54.28 10.40 51 42672 5208 29904547
Diabetic metabolic decompensation 51.66 10.40 29 42694 1317 29908438
Product leakage 50.81 10.40 19 42704 328 29909427
Hyperkalaemia 46.48 10.40 202 42521 65808 29843947
Drug ineffective 46.00 10.40 291 42432 340096 29569659
Appendicolith 44.21 10.40 23 42700 896 29908859
Product quality issue 43.52 10.40 88 42635 18686 29891069
Wrong product administered 42.41 10.40 42 42681 4576 29905179
Hypoglycaemia unawareness 38.88 10.40 12 42711 111 29909644
Device malfunction 37.74 10.40 52 42671 8059 29901696
Diabetic nephropathy 35.89 10.40 26 42697 1843 29907912
Hypoglycaemic encephalopathy 34.89 10.40 13 42710 222 29909533
Anti-insulin antibody 33.38 10.40 8 42715 24 29909731
Diabetes mellitus 33.28 10.40 133 42590 41732 29868023
Periodontitis 31.09 10.40 23 42700 1684 29908071
Cutaneous amyloidosis 30.85 10.40 8 42715 36 29909719
Loss of consciousness 29.43 10.40 204 42519 79171 29830584
Diabetic foot 29.06 10.40 27 42696 2718 29907037
Pulmonary valve stenosis congenital 28.66 10.40 10 42713 140 29909615
Diabetic neuropathy 27.44 10.40 31 42692 3928 29905827
Vitreous haemorrhage 26.79 10.40 23 42700 2087 29907668
Death 25.47 10.40 358 42365 356925 29552830
Insulin autoimmune syndrome 24.17 10.40 10 42713 228 29909527
Gallbladder neoplasm 23.51 10.40 6 42717 25 29909730
Pemphigoid 23.35 10.40 40 42683 7488 29902267
Chronic kidney disease 23.05 10.40 111 42612 37727 29872028
Diabetic macroangiopathy 23.00 10.40 5 42718 8 29909747
Liquid product physical issue 22.44 10.40 10 42713 275 29909480
Product complaint 22.31 10.40 34 42689 5772 29903983
Insulin resistance 21.28 10.40 12 42711 550 29909205
Diabetic coma 20.89 10.40 14 42709 875 29908880
Vomiting 20.81 10.40 434 42289 219384 29690371
Congenital cystic kidney disease 20.50 10.40 10 42713 339 29909416
Diabetic ketoacidotic hyperglycaemic coma 20.26 10.40 8 42715 161 29909594
Pancreatitis 19.38 10.40 103 42620 36387 29873368
Congenital bladder anomaly 18.67 10.40 9 42714 297 29909458
Hyperkinetic heart syndrome 18.50 10.40 7 42716 125 29909630
Diabetic complication 18.11 10.40 13 42710 908 29908847
Cystic fibrosis 17.83 10.40 19 42704 2255 29907500
Genitalia external ambiguous 17.49 10.40 8 42715 234 29909521
Adenocarcinoma pancreas 17.45 10.40 15 42708 1363 29908392
Pancreatic carcinoma 17.29 10.40 36 42687 7801 29901954
Gingival hypertrophy 17.16 10.40 16 42707 1617 29908138
Febrile neutropenia 17.15 10.40 86 42637 106607 29803148
Dry gangrene 17.09 10.40 8 42715 247 29909508
Agranulocytosis 16.86 10.40 69 42654 21873 29887882
Ketosis 16.81 10.40 9 42714 372 29909383
Renal aplasia 16.71 10.40 11 42712 667 29909088
Lymphangitis 16.62 10.40 10 42713 518 29909237
Treatment failure 16.58 10.40 15 42708 34664 29875091
Product use in unapproved indication 16.55 10.40 52 42671 73641 29836114
Hepatotoxicity 16.42 10.40 3 42720 18142 29891613
Hyperinsulinaemic hypoglycaemia 16.13 10.40 5 42718 47 29909708
Wrong technique in device usage process 15.52 10.40 12 42711 939 29908816
Incorrect dose administered 15.19 10.40 87 42636 31599 29878156
Rheumatoid arthritis 15.16 10.40 22 42701 41175 29868580
Skin ulcer 15.06 10.40 60 42663 18789 29890966
Foetal exposure during pregnancy 14.99 10.40 97 42626 36774 29872981
Cystic fibrosis related diabetes 14.62 10.40 6 42717 134 29909621
Toe amputation 14.61 10.40 17 42706 2224 29907531
Therapeutic product effect incomplete 14.61 10.40 16 42707 33818 29875937
Polycythaemia neonatorum 14.59 10.40 3 42720 3 29909752
Cardiac output decreased 14.22 10.40 11 42712 861 29908894
Blood ketone body increased 14.20 10.40 8 42715 366 29909389
Foetal hypokinesia 14.14 10.40 8 42715 369 29909386
Infective pulmonary exacerbation of cystic fibrosis 14.04 10.40 35 42688 8537 29901218
Insomnia 14.01 10.40 77 42646 93259 29816496
Truncus arteriosus persistent 13.82 10.40 4 42719 29 29909726
Diabetic foot infection 13.81 10.40 10 42713 708 29909047
Hypospadias 13.72 10.40 18 42705 2661 29907094
Hepatic encephalopathy 13.70 10.40 48 42675 14144 29895611
Lichen myxoedematosus 13.38 10.40 3 42720 6 29909749
Product physical issue 13.36 10.40 16 42707 2158 29907597
Product administration error 13.34 10.40 48 42675 14329 29895426
Neonatal respiratory depression 13.11 10.40 8 42715 425 29909330
Anxiety 13.02 10.40 75 42648 89796 29819959
Hepatic cirrhosis 12.84 10.40 51 42672 15948 29893807
Infusion related reaction 12.75 10.40 24 42699 40540 29869215
Heart disease congenital 12.60 10.40 12 42711 1246 29908509
Gangrene 12.36 10.40 23 42700 4591 29905164
Aggression 12.36 10.40 21 42702 36886 29872869
Appendicitis 12.15 10.40 27 42696 6117 29903638
Pneumobilia 12.03 10.40 4 42719 48 29909707
Jaundice neonatal 12.02 10.40 11 42712 1086 29908669
Disease progression 11.93 10.40 66 42657 79808 29829947
Eye haemorrhage 11.90 10.40 20 42703 3687 29906068
Device failure 11.89 10.40 15 42708 2133 29907622
Treatment noncompliance 11.89 10.40 69 42654 25184 29884571
Oedematous pancreatitis 11.84 10.40 7 42716 351 29909404
Postprandial hypoglycaemia 11.66 10.40 3 42720 13 29909742
Malaise 11.60 10.40 316 42407 166646 29743109
Drug withdrawal syndrome 11.49 10.40 7 42716 19802 29889953
Trisomy 18 11.46 10.40 6 42717 237 29909518
Hallucination 11.45 10.40 34 42689 49025 29860730
Spermatic cord disorder 11.31 10.40 3 42720 15 29909740
Impaired gastric emptying 11.24 10.40 18 42705 3188 29906567
Headache 11.11 10.40 188 42535 182118 29727637
Shock haemorrhagic 10.97 10.40 35 42688 9830 29899925
Hydrops foetalis 10.86 10.40 6 42717 264 29909491
Overdose 10.86 10.40 73 42650 84264 29825491
Ascites 10.85 10.40 88 42635 35833 29873922
Bronchopneumopathy 10.82 10.40 7 42716 412 29909343
Cold sweat 10.82 10.40 33 42690 9049 29900706
Post transplant distal limb syndrome 10.66 10.40 6 42717 274 29909481
Mucosal inflammation 10.53 10.40 17 42706 30477 29879278
Ankyloglossia congenital 10.46 10.40 6 42717 284 29909471
Neuropathic arthropathy 10.43 10.40 5 42718 163 29909592

Pharmacologic Action:

SourceCodeDescription
ATC A10AB05 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
INSULINS AND ANALOGUES
Insulins and analogues for injection, fast-acting
ATC A10AD05 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
INSULINS AND ANALOGUES
Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting
ATC A10AD06 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
INSULINS AND ANALOGUES
Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting
FDA CS M0011417 Insulin
FDA EPC N0000175453 Insulin Analog
MeSH PA D007004 Hypoglycemic Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Diabetes mellitus indication 73211009 DOID:9351

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Insulin receptor Kinase AGONIST DRUG LABEL DRUG LABEL

External reference:

IDSource
D04475 KEGG_DRUG
4021226 VUID
N0000148670 NUI
4021226 VANDF
4021394 VANDF
C0123677 UMLSCUI
CHEMBL1201496 ChEMBL_ID
CHEMBL1201664 ChEMBL_ID
DB01306 DRUGBANK_ID
D061267 MESH_DESCRIPTOR_UI
7541 INN_ID
D933668QVX UNII
118984445 PUBCHEM_CID
284810 RXNORM
15636 MMSL
17095 MMSL
327602 MMSL
37703 MMSL
d04697 MMSL
d04838 MMSL
007992 NDDF
009607 NDDF
325072002 SNOMEDCT_US
388452006 SNOMEDCT_US
427292001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
NOVOLOG HUMAN PRESCRIPTION DRUG LABEL 1 0169-2100 INJECTION, SOLUTION 100 [iU] INTRAVENOUS BLA 29 sections
NOVOLOG HUMAN PRESCRIPTION DRUG LABEL 1 0169-2101 INJECTION, SOLUTION 100 [iU] INTRAVENOUS BLA 29 sections
NovoLog Mix 70/30 HUMAN PRESCRIPTION DRUG LABEL 1 0169-2200 INJECTION, SUSPENSION 100 [iU] SUBCUTANEOUS BLA 27 sections
NovoLog Mix 70/30 HUMAN PRESCRIPTION DRUG LABEL 1 0169-2201 INJECTION, SUSPENSION 100 [iU] SUBCUTANEOUS BLA 27 sections
Fiasp HUMAN PRESCRIPTION DRUG LABEL 1 0169-3201 INJECTION, SOLUTION 100 [iU] SUBCUTANEOUS BLA 26 sections
Fiasp HUMAN PRESCRIPTION DRUG LABEL 1 0169-3204 INJECTION, SOLUTION 100 [iU] SUBCUTANEOUS BLA 26 sections
Fiasp HUMAN PRESCRIPTION DRUG LABEL 1 0169-3205 INJECTION, SOLUTION 100 [iU] SUBCUTANEOUS BLA 26 sections
NOVOLOG HUMAN PRESCRIPTION DRUG LABEL 1 0169-3303 INJECTION, SOLUTION 100 [iU] INTRAVENOUS BLA 29 sections
NovoLog Mix 70/30 HUMAN PRESCRIPTION DRUG LABEL 1 0169-3685 INJECTION, SUSPENSION 100 [iU] SUBCUTANEOUS BLA 27 sections
NovoLog Mix 70/30 HUMAN PRESCRIPTION DRUG LABEL 1 0169-3696 INJECTION, SUSPENSION 100 [iU] SUBCUTANEOUS BLA 27 sections
NOVOLOG HUMAN PRESCRIPTION DRUG LABEL 1 0169-6338 INJECTION, SOLUTION 100 [iU] INTRAVENOUS BLA 29 sections
NOVOLOG HUMAN PRESCRIPTION DRUG LABEL 1 0169-6339 INJECTION, SOLUTION 100 [iU] INTRAVENOUS BLA 29 sections
NOVOLOG HUMAN PRESCRIPTION DRUG LABEL 1 0169-7501 INJECTION, SOLUTION 100 [iU] INTRAVENOUS BLA 29 sections
NOVOLOG HUMAN PRESCRIPTION DRUG LABEL 1 50090-1664 INJECTION, SOLUTION 100 [iU] INTRAVENOUS NDA 29 sections
NOVOLOG HUMAN PRESCRIPTION DRUG LABEL 1 50090-1664 INJECTION, SOLUTION 100 [iU] INTRAVENOUS NDA 29 sections
NovoLog HUMAN PRESCRIPTION DRUG LABEL 1 50090-1665 INJECTION, SOLUTION 100 [iU] INTRAVENOUS NDA 29 sections
NOVOLOG HUMAN PRESCRIPTION DRUG LABEL 1 50090-1678 INJECTION, SOLUTION 100 [iU] INTRAVENOUS NDA 29 sections
NovoLog Mix 70/30 HUMAN PRESCRIPTION DRUG LABEL 1 50090-2272 INJECTION, SUSPENSION 100 [iU] SUBCUTANEOUS NDA 29 sections
NovoLog Mix 70/30 HUMAN PRESCRIPTION DRUG LABEL 1 50090-2272 INJECTION, SUSPENSION 100 [iU] SUBCUTANEOUS NDA 29 sections
NovoLog Mix 70/30 HUMAN PRESCRIPTION DRUG LABEL 1 50090-2273 INJECTION, SUSPENSION 100 [iU] SUBCUTANEOUS NDA 29 sections
NovoLog Mix 70/30 HUMAN PRESCRIPTION DRUG LABEL 1 50090-2273 INJECTION, SUSPENSION 100 [iU] SUBCUTANEOUS NDA 29 sections
NovoLog Mix 70/30 HUMAN PRESCRIPTION DRUG LABEL 1 50090-4074 INJECTION, SUSPENSION 100 [iU] SUBCUTANEOUS BLA 27 sections
NovoLog Mix 70/30 HUMAN PRESCRIPTION DRUG LABEL 1 50090-4085 INJECTION, SUSPENSION 100 [iU] SUBCUTANEOUS BLA 27 sections
Insulin Aspart HUMAN PRESCRIPTION DRUG LABEL 1 50090-4955 INJECTION, SOLUTION 100 [iU] INTRAVENOUS BLA 28 sections
Insulin Aspart HUMAN PRESCRIPTION DRUG LABEL 1 50090-4956 INJECTION, SOLUTION 100 [iU] INTRAVENOUS BLA 28 sections
.Insulin Aspart Protamine and Insulin Aspart HUMAN PRESCRIPTION DRUG LABEL 1 50090-4959 INJECTION, SUSPENSION 100 [iU] SUBCUTANEOUS BLA 28 sections
NovoLog Mix 70/30 HUMAN PRESCRIPTION DRUG LABEL 1 54868-5201 INJECTION, SUSPENSION 100 [iU] SUBCUTANEOUS NDA 31 sections
NovoLog Mix 70/30 HUMAN PRESCRIPTION DRUG LABEL 1 54868-5327 INJECTION, SUSPENSION 100 [iU] SUBCUTANEOUS NDA 31 sections
NovoLog HUMAN PRESCRIPTION DRUG LABEL 1 64725-0750 INJECTION, SOLUTION 100 [iU] INTRAVENOUS NDA 28 sections
NovoLog HUMAN PRESCRIPTION DRUG LABEL 1 68258-8899 INJECTION, SOLUTION 100 [iU] INTRAVENOUS NDA 29 sections